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Abstract 
The varieties of infections caused by Helicobacter pylori may be due to differences in bacterial genotypes and virulence factors as well as 
environmental and host-related factors. This study aimed to investigate the prevalence of cagA and vacA genes among H. pylori-infected 
patients in Iran and analyze their relevance to the disease status between two clinical groups via a meta-analysis method. 
Different databases including PubMed, ISI, Scopus, SID, Magiran, Science Direct, and Medlib were investigated, and 23 relevant articles 
from the period between 2001 and 2012 were finally analyzed. The relevant data obtained from these papers were analyzed by a random-
effects model. Data were analyzed using R software and STATA. The prevalence of cagA and vacA genes among H. pylori-infected patients 
was 70% (95% CI, 64–75) and 41% (95% CI, 24.3–57.7), respectively. The prevalence of duodenal ulcers, peptic ulcers, and gastritis among 
cagA+ individuals was 53% (95% CI, 20–86), 65% (95% CI, 34–97), and 71% (95% CI, 59–84), respectively. Odds ratio (OR) between 
cagA-positive compared with cagA-negative patients showed a 1.89 (95% CI, 1.38–2.57) risk of ulcers. In conclusion, the frequency of cagA 
gene among H. pylori strains is elevated in Iran and it seems to be more frequently associated with gastritis. Therefore, any information about 
cagA and vacA prevalence among different H. pylori-infected clinical groups in the country can help public health authorities to plan 
preventive policies to reduce the prevalence of diseases associated with H. pylori infection. 
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Introduction 
Helicobacter pylori infection is a prevalent disease 
that affects more than half of the world's population. It 
is the most common infectious bacteria of the stomach 
and can persist in many conditions in which other 
bacteria are not able to live [1]. H. pylori is a Gram-
negative and microaerophilic bacillus that is 
recognized as a special pathogen of the human 
stomach. It causes a chronic inflammation of gastric 
mucosa by infiltration of neutrophils, lymphocytes, 
and plasma cells into the gastric mucosa. This bacillus 
is the etiological cause of peptic ulcers, 
adenocarcinoma of stomach, and MALT lymphoma, 
and has been associated with ischemic heart disease, 
adenotonsillar disease, and other types of malignancies 
[1-4]. H. pylori is able to colonize the human gastric 
mucosa and create a persistent infection associated 
with acute or chronic inflammation [5]. Mucosal 
gastritis occurs in all infected patients; however, only 
a small number of these patients show clinical 
symptoms and relevant complications such as peptic 
ulcers, gastritis, or gastric cancer [6]. Contamination 
with H. pylori in developing countries is high, and a 
prevalence of more than 80% has been reported. Also, 
the severity of H. pylori-dependent gastro-duodenal 
diseases is influenced by bacterial, environmental, and 
genetic factors [2]. The relevant mechanisms involved 
in different aspects of the diseases have not been fully 
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elucidated yet; however, a combination of different 
virulence factors in different H. pylori strains may 
play a role [6]. Nevertheless, the cytotoxin-associated 
gene A (cagA) and the vacuolating cytotoxin (vacA) 
are the two main H. pylori virulence factors identified 
among the bacterial markers associated with 
pathogenesis of different strains [6].  
Mounting evidence indicates a positive 
relationship between the presence of H. pylori cagA+ 
strains and the development of peptic/duodenal ulcers 
and gastric cancer in infected patients [5].  
H. pylori cagA+ strains carry a 40 kbp 
pathogenicity island, which contains the cagA gene 
that encodes cagA and genes that encode a type IV 
secretion system, through which cagA and other 
bacterial virulence factors are injected into host cells 
[7]. The cagA gene is present in about 50%–70% of 
strains, and in some Asian countries, its prevalence is 
about 90% [2]. According to variation seen at its 
tyrosine phosphorylation-SHP-2 binding site, cagA has 
been sub-classified in two main types, Western cagA 
and East Asian cagA, the latter being more 
biologically active and accounting for the high 
incidence of gastric carcinoma in East Asian countries 
[7]. After injection into host epithelial cells, cagA is 
tyrosine phosphorylated and activates the Ras-MAPK 
(mitogen-activated protein kinase) kinase pathway. 
This induces cell growth and motility of gastric 
epithelial cells along with alteration of epithelial cell 
differentiation [7]. 
VacA is an 88 kDa protein toxin that was 
identified by its ability to induce the formation of 
cytoplasmic vacuoles in cultured cells [8]. It has been 
suggested that VacA acts as a multifunctional toxin. 
Indeed, VacA has been reported to induce cell damage 
of gastric epithelial cells and to exert an 
immunosuppressive action through inhibition of 
antigen presentation and T-lymphocyte activation. 
Although the gene encoding VacA (vacA) is present in 
all H. pylori strains, allele variations exist in the VacA 
secretion signal sequence (allele types s1 or S1) and 
the mid-region (alleles types m1 or m2) [9]. 
The isolates carrying vacA and cagA create more 
severe inflammation. There are many studies, with 
different findings, about the existence or absence of 
cagA and its treatment
 
[3].  According to different 
studies, isolates possessing cagA increase the risk of 
special clinical aspects, but their incidences are not 
predictable [6]. 
This study aimed to investigate the prevalence of 
cagA and vacA among H. pylori-infected patients 
developing peptic ulcer disease (PUD), non-ulcer 
disease (NUD), gastritis, and gastric cancer in Iran 




All associated published papers in national and 
international journals of PubMed, Scopus, ISI, 
Magiran, IranMedex, Science Direct, Medlib, and SID 
databases were evaluated. Searching was done in a 
systematic way using keywords cagA, vacA, 
prevalence, H. pylori, Iran, and meta-analysis (both in 
English and Persian). 
 
Paper selection 
First, a list of 67 papers and abstracts yielded by 
the keyword search, was prepared and evaluated for 
relevance. Of these studies, 17 were excluded because 
they were repetitive, 8 were not consistent with the 
study criteria, the full texts of 11 papers were not 
accessible and their abstracts did not contain enough 
information, and 8 papers did not reveal the 
prevalence of cagA; all of these papers were 
withdrawn (Flowchart 1). Finally, 23 relevant papers 
[2-4,6,10-28] were identified. Their data were entered 
into the data collection forms, and then these data were 
entered into Microsoft Excel and were analyzed using 
R software (version 11.2) and STATA (version 10). 
 
Statistical analysis 
The main objective of the study was to evaluate 
the prevalence of cagA and vacA; therefore, its 
variance was estimated by binominal distributions. To 
pool prevalence reported by different studies, 
weighting averaging was used. Each study was given a 
weight equal to its inverse variance. For evaluation of 
heterogeneity, Q test and I
2
 index, at the type I error of 
smaller than 0.10, were applied. Wherever the results 
of studies were heterogeneous, the analysis was 
performed using a random-effects model. The random-
Flowchart 1. The flowchart of selected articles for final 
analysis 
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effects model was used because there was significant 
heterogeneity among the results of the studies (I
2
 = 
92%, p = 0.000). To pool the results of the studies, two 
main approaches were used: the fix effects model and 
the random-effects model. When heterogeneity among 
the results of the studies was not significant, the fix 
effects model was used to pool analysis and verses. In 
a two-by-two cross-sectional table, odds ratio was 





The 95% confidence interval (CI) was computed 
using the formula: 















Funnel plot is a graphical detection of publication 
bias. The funnel plot is a bivariate scatter plot (x, y) of 
the study sample size against the study estimate of 
treatment difference or effect size. There is a formal 
test for publication bias based on linear regression 
analysis. It includes both intercept and slope 
parameters and is given by yi = α + βxi + εi, 
for i = 1, . . . , r, where r is the number of studies, 
yi is the standardized estimate, xi is the precision of 
studies, and εi is the error terms. 
 






































2006 Tehran 54   42  35 (22-48)   26   
Farshad   [6]  2009 Shiraz 65 30 35 
14 ± 
41.3 
57 (45-69) 48 (36-60) 60 37.2    
Latifi-Navid 
[11] 
2010 Tehran 144     72 (65-79)      
Shokri 
Shirvani [12] 
2008 Babol 30     80 (66-94)   73 67 91.7 




 64 (52-77) 41.66 58.33    
Khodaei [4] 2013 Tehran 140 105 35 
7.3 ± 
41.1 
38 (29-46) 70 (62-78) 69.23 68.6 81 70 56.3 
Mollabashi  
[13] 
2012 Isfahan 16     19 (-0.0-38)      
Souod [14] 2013 Shahrekord 164   
17 ± 
47 
17 (11-22) 92 (88-96)   13 9 89.63 
Bazargani  
[15] 
2007 Shiraz 120 51 69 18-68  69 (61-77) 82.3 59.4    
Aqajani [16] 2002 Shahrod 135     75 (68-82)      
Shirazi [17] 2008 Tehran 92 58 34   85 (78-92) 69.55 64.7 100 90  
Goudarzi [2] 2012 Tehran 84   56.6  64 (54-74)    77 50 
Ghasemian 
Safaei [18] 
2008 Isfahan 100     68 (59-77)   73  65 
Douraghi  
[19] 
2008 Tehran 120 17 81   84 (78-91) 94.1 74.1    
Molaei  [20] 2009 Tehran 86    91 (85-97) 77 (68-86)      
Ghasemi 
kebria [21] 
2011 Golestan 683     58 (54-61)      
Ghotaslou  
[23] 
2013 Tabriz 115 62 53  37 (29-46) 69 (60-78) 40.9 27.8    
Nahaei [36] 2008 Tabriz 150 33 117 37.5 30 (23-37) 83 (77-89) 93.9 80.3    
Bojary  [24] 2004 Tehran 92   47  70 (61-79)      
Nawfal [22] 2008 Tehran 59 17 42 
14 ± 
40 




2006 Shiraz 286   
16.6 ± 
45.3 
33 (28-39) 77 (72-82)    81 74.4 
Jafari  [27] 2008 Tehran 96 19 74 44 29 (20-38) 76 (67-85) 79 74.3    
Dabiri [28] 2009 Tehran 124 22 91 
17 ± 
46 
38 (27-49) 68 (60-76) 55 73    
PUD: peptic ulcer disease; NUD: non-ulcer disease 
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Results 
Twenty-three relevant papers from between 2001 
and 2012 in Iran were included in the meta-analysis 
(Table 1). The total number of evaluated patients 
infected by H. pylori was 3,011. Due to high 
heterogeneity of the studies' findings, a random-effects 
model was applied for all further steps. The prevalence 
of cagA among H. pylori-infected patients was 70% 
(95% CI, 64–75) (Figure 1) and 71% (95% CI, 65–77) 
in 12 studies from Tehran province. The vacA 
prevalence in total was 38.2 (95% CI, 22.3–54); in 
NUD, it was 29.7% (95% CI, 21.8–37.7) and in PUD, 
38.2% (95% CI, 22.3–54) (Figure 2). The cagA 
prevalence for Shiraz, Babol, Isfahan, Shahrkord, 
Shahroud, Golestan, and Tabriz was 65% (95% CI, 
51–80), 80% (95% CI, 66–94), 44% (95% CI, 4–92), 
92% (95% CI, 88–96), 75% (95% CI, 67–82), 58% 
(95% CI, 54–61), and 76% (95% CI, 62–91), 
respectively. In 11 studies, the prevalence of cagA 
among patients with PUD and those with NUD was 
analyzed (Figure 3). Patients with positive cagA 
compared to those with negative cagA showed risk of 
peptic ulcer of 1.89 (95% CI, 1.38–2.57) (Table 2). A 
statistically significant relationship between cagA 
positivity and H. pylori infection was found when data 
of all eleven studies were combined. The prevalence 
of duodenal ulcers (reported by six studies), peptic 
ulcers (reported by six studies), and gastritis (reported 
by six studies) among individuals infected with H. 
pylori cagA+ strains was 53% (95% CI, 20–86), 65% 
(95% CI, 34–97), and 71% (95% CI, 59–84), 
respectively. According to the publication bias figure, 
the effect of bias in these studies was not significant. 
In fact, most studies were located inside the funnel 
plot, thus demonstrating that the results of most 
relevant studies performed in Iran were included in the  





Prevalence  (random effects model) 
(95% CI) 
Mean age of participants 12 44.24 
Prevalence of cagA 23 64-75 )70) 
Prevalence of cagA in Tehran 12 65-77 )71) 
Prevalence of cagA in Shiraz 3 51-80 )65) 
Prevalence of cagA in Babol 1 66-94 )80) 
Prevalence of cagA in Isfahan 2 4-92 )44) 
Prevalence of cagA in Shahrkord 1 88-96 )92) 
Prevalence of cagA in Shahrod 1 67-82 )75) 
Prevalence of cagA in Golestan 1 54-61 )58) 
Prevalence of cagA in Tabriz 2 62-91 )76) 
Prevalence of duodenal ulcer cagA+ 6 20-86 )53) 
Prevalence of gastric ulcer cagA+ 6 34-97 )65) 
Prevalence of gastritis cagA+ 6 59-84)71) 
Prevalence of vacA (total) 9 41 (24-58) 
Prevalence of vacA (PUD) 6 30 (22-38) 
Prevalence of vacA (NUD) 6 38 (22-54) 
 OR 
95% CI 
(random effects model) 
Prevalence of gastric cancer (total) 8.9 2.4-15.4 
Prevalence of gastritis (total) 58.5 29.3-87.6 
Prevalence of gastric cancer cagA+ 0.10 0.02-0.18 
Prevalence of gastritis cagA+ 0.31 -0.03-0.66 
Prevalence of gastric cancer cagA- 0.21 -0.10-0.53 
Prevalence of gastritis cagA- 0.65 0.45-0.86 
Prevalence of gastric cancer vacA 0.08 -0.01-0.18 
Prevalence of gastritis vacA 0.53 0.23-0.84 
Prevalence of cagA+ 0.70 0.61-0.79 
Prevalence of cagA+ (NUD) 0.64 0.52-0.76 
Prevalence of cagA+ (PUD) 0.588 0.389-0.788 
Prevalence of cagA- 0.310 0.205-434 
Prevalence of cagA- (NUD) 0.547 -0.005-1.10 
Prevalence of cagA- (PUD) 0.29 0.127-0.452 
PUD: peptic ulcer disease; NUD: non-ulcer disease 
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  Figure 1. Prevalence of cagA and its 95% confidence interval 
using a random-effects model .Midpoint of each line segment 
represents the estimated prevalence in the study. Rhombic 
mark shows the prevalence in Iran, extracted from all studies. 
Figure 2. Prevalence of vacA and its 95% confidence interval 
using a random-effects model. 
Midpoint of each line segment represents the estimated 
prevalence in the study. Rhombic mark shows the prevalence 
in Iran, extracted from all studies. 
Figure 3. The results of meta-analysis of H. pylori infections 
among PUD and NUD individuals. 
Odds ratio (OR) and 95% confidence intervals for each study and in 
summary with weighting in a fixed-effects model are shown. OR > 1.0 
indicates the higher probability of eradication failure of cagA-negative 
H. pylori-infected patients compared with cagA-positive H. pylori-
infected patients. 
Figure 4. Begg’s funnel plot for publication bias in the risk 
difference (RD) analysis. 
Each circle represents the RDs for eradication success between cagA-
positive and cagA-negative according to the standard error of each RDs. 
The diameter of each circle represents the weight in the meta-analysis. 
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analysis (Figure 4). Interpretation of meta-regression 
showed that there was no significant relationship 
between prevalence of cagA and the year of study (p = 
0.57) (Table 3). 
 
Discussion 
The current meta-analysis study evaluated the 
prevalence of cagA and vacA in a total sample size of 
3,011 patients infected with H. pylori in Iran between 
2001 and 2012. In the current study, the prevalence of 
cagA among patients infected with H. pylori was 70%, 
which was in accordance with reports from Iraq (71%) 
and Turkey (78%) [25,29]. It was also consistent with 
reports from Europe and North America [30,34]. 
However, the prevalence obtained from the present 
study was lower than that reported from Southeast 
Asia (93% positive for cagA) by a similar meta-
analysis study [35]. Podzorski et al. from the United 
States reported that only 66% of H. pylori isolates 
were positive for cagA [36]. Zhou et al. from China 
reported a prevalence of 93.9% for cagA among H. 
pylori isolates [37]; however, this figure for the 
Netherlands, Germany, Estonia, and Sri Lanka was 
46%, 87.2%, 87%, and 45%, respectively [38]. A 
study from Brazil reported a prevalence of 81.7% for 
the cagA gene among H. pylori isolates [39]. There is 
a variety in the distribution of cagA among H. pylori 
isolates in different parts of the world [40]. According 
to evidence, more than 90% of isolates form Eastern 
populations included cagA [41]. The prevalence found 
in the current study was different from that reported 
from South and East Asian countries, in which a 
prevalence of more than 90% was reported [42,43]. 
For example, a prevalence of 97%, 95%, 94%, and 
90% was reported for cagA among H. pylori isolates 
from Korea, Japan, Malaysia, and China, respectively 
[44-45,23-24]. Our findings were more similar to 
those reported from European and American countries 
that ranged between 60% and 70% [46]. In partial 
support of this, a recent study showed that H. pylori 
isolates from infected patients in Iran displayed a large 
variability in the polymorphisms of cagA and vacA 
genes [47]. This may be due to the location of this 
country in the Middle East; it may have a combination 
of Western and Eastern isolates of H. pylori [47]. 
CagA pathogenicity island of is one of the most 
important markers of H. pylori pathogenesis, so 
isolates without this island have lower abilities for 
pathogenesis. The cagA gene is the biggest segment of 
this island; therefore, the presence of the cagA gene 
can be an existence marker of this island [19]. The 
prevalence of isolates with cagA among different 
geographical areas is also different, which may be 
related to the difference between studied populations 
and/or genetic varieties of investigated isolates. This 
finding of our study was in accordance with reports 
from East Asian countries [48].  
A previous meta-analysis study demonstrated that 
the prevalence of H. pylori infection in Iran was 
50.7% (95% CI, 44.4–56.9) [49]. The frequencies of 
peptic ulcers and gastric malignancy are highly 
affected by ethnical and geographical variables; 
therefore, these findings combined with the lower 
efforts for H. pylori eradication in Iran as well as a 
considerable of recurrent infections may indicate a 
high developmental process of Iranian isolates [11]. 
Mounting evidence demonstrates that the genetic 
variability of H. pylori strains is dependent on the 
geographical and ethnic status of human hosts [11]. A 
study by Latifi et al. analyzed the sequences of 
housekeeping genes and revealed that genetic 
characteristics of H. pylori in Iran were affected by 
genetic interchanges with neighboring countries, and 
that there were considerable ethnical and geographical 
differences inside Iran [50]. 
 This finding was in accordance with our results 
about differences in the local prevalence of cagA 
obtained from Tehran (71%), Shiraz (65%), Babol 
(80%), Isfahan (44%), Shahrkord (92%), Shahroud 
(75%), Golestan (58%), and Tabriz (76%). Internal 
studies on the cagA gene in Iran showed contradictory 
results; in some studies, the difference between 
reported prevalence of cagA was more than 50%. One 
of the reasons for these contradictory results was the 
different sensitivities of the methods used for 
identification of cagA and H. pylori infections in 
different studies [51-53]. H. pylori has been confirmed 
as an important pathogen in the human gastric tract, 
and different isolates of these bacteria cause a variety 
of gastrointestinal disorders resulting in complications 
Table 3. Source of heterogeneity by multivariate meta-regression analysis 
P value Standard error Coefficient Factors 
0.57 0.0112 -0.0065 Published year 
0.89 0.000024 0.000033 Sample Size 
 
Sayehmiri et al. – cagA and vacA prevalence among H. pylori in Iran    J Infect Dev Ctries 2015; 9(7):686-696. 
692 
such as injury of gastric mucosa, transformation of 
tissue stratum, chronic inflammation, chronic gastritis, 
PUD, and gastric malignancy. However, not all 
involved patients suffer from these complications, and 
more than 50% of involved patients do not show any 
symptoms. Genetic pathogenesis of different isolates 
and environmental characteristics are essential factors 
related to this discrepancy [6,24]. CagA as a product 
of the cagA gene has been introduced as the main 
pathogen factor in H. pylori and acts as a provoker for 
different disorders related to this microorganism. The 
effects of CagA in the induction of local inflammatory 
response, progress of PUD, and gastric malignancy 
have been recognized [52,64]. Our study showed a 
higher frequency of patients with cagA among patients 
with PUD compared to those with NUD. It has been 
reported that patients with NUD are more resistant to 
H. pylori-eradication therapy than individuals with 
PUD. Additionally, there is some influence of cagA 
status on eradication in NUD patients, a possibility 
which warrants further investigation given the link 
between cagA status and improvement of symptoms in 
NUD patients in whom eradication is successful [55]; 
however, this difference was found not to be 
significant. Almost all previous studies have shown a 
higher frequency of positive cagA among patients with 
PUD compared to those with NUD; however, these 
differences were statistically significant in only some 
of these studies [56-58] (inconsistent with our results) 
and not significant in others [59-61] (consistent with 
our results). In further support of a correlation between 
cagA positivity and PUD, it has been demonstrated 
that cytotoxic cagA-positive strains cause more 
profound inhibition of mucin synthesis, thus 
suggesting that the increased inhibitory effect of cagA-
positive, cytotoxin-producing strains on mucin 
synthesis increases the risk of developing peptic 
ulceration [48]. 
In the populations of Western countries, particular 
genotypes of the vacuolating cytotoxin gene vacA 
(vacA s, signal region variants; vacA m, middle region 
variants) of H. pylori have been associated with high 
risk of developing peptic ulcers and gastric cancer 
[62]. 
In the current study, the prevalence of duodenal 
ulcers, peptic ulcers, and gastritis among patients with 
positive cagA was 53%, 65%, and 71%, respectively. 
In previous studies, the presence of cagA was 
associated with severe gastric disorders such as severe 
gastritis, duodenal ulcers, peptic ulcers, and gastric 
malignancy [63-65]. Our findings, similar to these 
studies, showed high frequency of these disorders 
among patients with cagA. Aydin et al. reported a 
prevalence of 72.2% cagA among isolates detected 
from patients with peptic ulcers in Turkey [66]. 
Figueredo and colleagues reported a prevalence of 
56%, 90%, 88%, and 88% of cagA among isolates 
detected from patients with gastritis, duodenal ulcers, 
peptic ulcers, and gastric cancer, respectively [67]. 
Arents et al. showed a higher prevalence in the 
Netherlands of cagA among patients with peptic ulcers 
compared with patients with other diseases [68]. Also, 
other studies from Iraq [25], Turkey [29], and Saudi 
Arabia [69] reported a relationship between the cagA 
gene and gastric cancer or peptic ulcers. A study from 
Italy demonstrated that the prevalence of the cagA 
gene among patients with duodenal ulcers and peptic 
ulcers was 86.1% and 96.4%, respectively [70]. Gzyl 
et al. reported a positive relationship between cagA 
gene and incidence of acute gastritis among child and 
adult patients [71]. According to different reports, 
either numbers or features of different motifs are 
changed by alteration of geographical locations, and 
their clinical outcomes are also affected by this 
variation. Western Asian isolates are therefore 
different from Eastern Asian isolates [11], and Eastern 
Asian isolates are more associated with gastric cancer 
than are Western isolates [72]. For example, studies by 
Zhou et al. [37] and Chen et al. [57] reported the 
prevalence of cagA among isolates associated with 
peptic ulcers and gastric cancers to be 100% and 94%, 
respectively. Some studies from Western countries 
reported a relationship between severity of diseases 
and the prevalence of cagA among associated isolates, 
but studies from East Asia reported no significant 
relationship between these variables [73-74] and 
concluded that clinical results could not be predicted 
by the prevalence of cagA among Asian countries [75-
76]. Moreover, meta-analyses identified a significant 
relationship between vacA m-region genotype and 
cagA status and the development of diseases in 
Southeast Asia. Importantly, most of the H. pylori 
strains isolated from countries with high incidences of 
gastric cancer and anti-cagA antibody can be used as a 
biomarker for gastric cancer even in East Asian 
countries [55,77-78]. 
Our study showed higher frequency of the cagA 
gene among patients with gastritis, but this was not 
statistically significant. Despite the difference in the 
frequency of cagA among different types of diseases, a 
relationship between the presence or absence of cagA 
and the severity of disease can be assumed. The 
current study showed that more than 70% of Iranian 
isolates were positive for cagA. High frequency of 
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cagA among isolates does not necessarily lead to 
severe diseases such as severe gastritis, peptic ulcers, 
or gastric cancer; however, this finding may be due to 
excess numbers of alleles among cagA genes in 
Iranian isolates.  
Discrepancies between different reports about the 
severity of immune responses and the incidence of 
clinical outcomes for isolates with positive cagA may 
be associated with environmental and genetic factors 
of either host or bacteria. Examples for these are gene 
polymorphisms of inflammatory cytokines, difference 
in individual immune systems, and genetic differences 
in bacterial virulence genes such as vacA, iceA, and 
several genes included in the cag pathogenicity island 
[79-80] 
Polymorphisms in interleukin (IL)-1B, IL-1RN, 
IL-8, IL-10, and tumor necrosis factor alpha (TNF-α), 
which are involved in H. pylori infection, increase risk 
of gastric cancer [81-82]. 
Despite the relationship of these well-known genes 
with clinical outcomes, it seems this subject is still a 
controversial problem; for clarity of this ambiguity, 
execution of studies with bigger sample sizes and in 
different geographical places of Iran is suggested [10]. 
Some limitations of this study were the lack of 
comparison between the prevalence of cagA gene and 
age/gender groups of patients; the lack of comparison 
between peptic ulcers and age/gender groups; and the 
unavailability of some studies associated with 
prevalence of cagA. 
 
Conclusions 
Considering the high prevalence of H. pylori 
infection and its serious outcomes, early diagnosis of 
this bacteria and characterization of cagA and vacA 
status of H. pylori strains using polymerase chain 
reaction (PCR) is important for the prevention and 
timely treatment of associated infection. In this study, 
we revealed a high prevalence of the cagA gene in Iran 
and a more significant correlation between cagA gene 
positivity in gastritis compared with other diseases. 
Due to dispersal uniformity of cagA genes among all 
disease groups, the presence of the cagA gene cannot 
be considered solely as a determinant marker of 
clinical outcome for H. pylori infection. Therefore, the 
clinical features of diseases associated with H. pylori 
infection are mostly related to bacterial, 
environmental, and host-related factors. Due to the 
complexity features of diseases associated with H. 
pylori infection, identification of new acuteness-
related factors and expansion of their monitoring in the 
different geographical areas is necessary. 
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